Dislipidemi

Authors

M. Mustafa Demirpençe

Synopsis

This chapter addresses the diagnosis, screening, clinical findings, and treatment approaches for dyslipidemia, which is one of the most critical preventable risk factors for cardiovascular diseases (CVD). Dyslipidemia, typically asymptomatic and widespread, constitutes the core mechanism of atherosclerosis pathogenesis. Diagnosis and risk stratification rely on a standard lipid panel comprising Total-C, LDL-C, HDL-C, non-HDL-C, and ApoB. Treatment decisions are guided by the patient's 10-year CVD risk level calculated via the SCORE system alongside baseline LDL-C values. Non-pharmacological interventions, including a diet low in saturated fats, weight control, regular aerobic exercise, and smoking cessation, form the primary foundation. Statins represent the first-line pharmacotherapy by inhibiting the HMG-CoA reductase enzyme to lower LDL-C levels and reduce CVD mortality. In cases of statin intolerance, contraindications, or insufficient response, non-statin options such as bile acid sequestrants (colesevelam), ezetimibe, fibrates, niacin, omega-3 fatty acids, or PCSK9 inhibitors (alirocumab, evolocumab) can be utilized either as monotherapy or combination therapy. Additionally, LDL/plasma apheresis serves as a vital intervention in severe cases such as familial hypercholesterolemia or hypertriglyceridemia-induced acute pancreatitis.

References

Yang Q, Zhong Y, Ritchey M, et al. Predicted 10-Year Risk of Developing Cardiovascular Disease at the State Level in the U.S. American Journal of Preventive Medicine. 2015;48(1):58-69. doi:10.1016/j. amepre.2014.09.014.

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144.

Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245. doi:10.1161/ CIR.0b013e31828124ad.

Bayram F, Kocer D, Gundogan K, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. Journal of Clinical Lipidology. 2014;8(2):206-216. doi:10.1016/j.jacl.2013.12.011.

Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-1309. doi:10.1001/jama.2012.366.

Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol. 2012;110(10):1468-1476. doi:10.1016/j.amjcard.2012.07.007.

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-2397. doi:10.1056/NEJMoa1410489.

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJ- Moa1615664.

Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999-3058. doi:10.1093/eurheartj/ehw272.

TEMD Dislipidemi Tanı ve Tedavi Klavuzu(2019)

Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151-167. doi:10.1016/j.cjca.2012.11.032.

Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology. 2011;5(3):133-140. doi:10.1016/j.jacl.2011.03.001.

Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association Of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Dyslipidemia And Prevention Of Cardiovascular Disease – Executive Summary Complete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017;23(4):479-497. doi:10.4158/EP171764.GL.

Sonmez A, Associate Professor in Medicine, Gulhane Military Medical Academy, School of Medicine, Department of Endocrinology and Metabolism, Ankara, Turkey. Which One to Endorse Among the Multitude of Lipid Guidelines? European Endocrinology. 2014;11(1):32. doi:10.17925/EE.2015.11.01.32.

Goldstein JL, Brown MS. A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell. 2015;161(1):161-172. doi:10.1016/j.cell.2015.01.036.

Moore KJ, Tabas I. Macrophages in the Pathogenesis of Atherosclerosis. Cell. 2011;145(3):341-355. doi:10.1016/j. cell.2011.04.005.

Tuzcu EM, Kapadia SR, Tutar E, et al. High Prevalence of Coronary Atherosclerosis in Asymptomatic Teenagers and Young Adults: Evidence From Intravascular Ultrasound. Circulation. 2001;103(22):2705-2710. doi:10.1161/01. CIR.103.22.2705.

Oren A, Vos LE, Uiterwaal CSPM, Grobbee DE, Bots ML. Cardiovascular Risk Factors and Increased Carotid Intima-Media Thickness in Healthy Young Adults: The Atherosclerosis Risk in Young Adults (ARYA) Study. Arch Intern Med. 2003;163(15):1787- 1792. doi:10.1001/archinte. 163.15.1787.

Arıcı M, Birdane A, Güler K, et al. [Turkish Hypertension Consensus Report]. Turk Kardiyol Dern Ars. 2015;43(4):402-409. doi:10.5543/tkda.2015.16243. Türkiye’de Lipid Düşürücü Tedavilerine Yönelik Sağlık Uygulama Tebliği (SUT) Kuralları 97

Xydakis AM, Ballantyne CM. Role of non–high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials. Current Opinion in Cardiology. 2003;18(6):503.

Lu W, Resnick HE, Jablonski KA, et al. Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes: The Strong Heart Study. Diabetes Care. 2003;26(1):16-23. doi:10.2337/dia-care.26.1.16.

Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel. Journal of Internal Medicine. 2006;259(3):247-258. doi:10.1111/j.1365-2796.2006.01616.x.

Sattar N, Williams K, Sniderman AD, D’Agostino R, Haffner SM. Comparison of the Associations of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study. Circulation. 2004;110(17):2687-2693. doi:10.1161/01.CIR.0000145660.60487.94.

Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the IN-TERHEART study): case-control study. The Lancet. 2004;364(9438):937-952. doi:10.1016/S0140-6736(04)17018-9.

Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction. Circulation. 2008;118(20):2047-2056. doi:10.1161/CIRCULATIONAHA.108.804146.

Sidhu D, Naugler C. Fasting Time and Lipid Levels in a Community-Based Population: A Cross-sectional Study. Arch Intern Med. 2012;172(22):1707-1710. doi:10.1001/archinternmed.2012.3708.

Doran B, Guo Y, Xu J, et al. Prognostic Value of Fasting vs. Non-Fasting Low Density Lipoprotein Cholesterol Levels on Long-term Mortality: Insight from the National Health and Nutrition Survey III (NHANES-III). Circulation. 2014;130(7): CIRCULATIONAHA.114.010001-CIRCULATIONAHA.114.010553. doi:10.1161/CIRCULATIONAHA.114.010001.

Marti-Soler H, Gubelmann C, Aeschbacher S, et al. Seasonality of cardiovascular risk factors: an analysis including over 230 000 participants in 15 countries. Heart. 2014;100(19):heartjnl–2014–305623–1523. doi:10.1136/ heartjnl-2014-305623.

Schubert CM, Rogers NL, Remsberg KE, et al. Lipids, lipoproteins, lifestyle, adiposity and fat-free mass during middle age: the Fels Longitudinal Study. International Journal of Obesity 2005 30:2. 2006;30(2):251-260. doi:10.1038/sj.ijo.0803129.

Namekata T, Moore DE, Suzuki K, et al. Biological and lifestyle factors, and lipid and lipoprotein levels among Japanese Americans in Seattle and Japanese men in Japan. Int J Epidemiol. 1997;26(6):1203-1213. doi:10.1093/ ije/26.6.1203.

Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia And Prevention of Cardiovascular Disease. Endocrine Practice. 2017;23(Supplement 2):1-87. doi:10.4158/EP171764.APPGL.

Mente A, de Koning L, Shannon HS, Anand SS. A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart Disease. Arch Intern Med. 2009;169(7):659-669. doi:10.1001/archin-ternmed.2009.38.

Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor. European Heart Journal. 2013;34(42):3259-3267. doi:10.1093/eurheartj/eht352.

Alves AJ, Viana JL, Cavalcante SL, et al. Physical activity in primary and secondary prevention of cardiovascular disease: Overview updated. World Journal of Cardiology. 2016;8(10):575-583. doi:10.4330/wjc.v8.i10.575.

Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Preventive Medicine. 2003;37(4):283-290. doi:10.1016/ S0091-7435(03)00110-5.

Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ. 2011;342(feb221):d636-d636. doi:10.1136/bmj.d636.

Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JAC. 2014;63(25 Part B):2960-2984. doi:10.1016/j.jacc.2013.11.003.

Rubenfire M, Coletti AT, Mosca L. Treatment strategies for management of serum lipids: Lessons learned from lipid metabolism, recent clinical trials, and experience with the H mg CoA reductase inhibitors. Progress in Cardiovascular Diseases. 1998;41(2):95-116. doi:10.1016/S0033-0620(98)80007-8.

B M, J E, L B, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet. 2012;380(9841):581-590. doi:10.1016/ S0140-6736(12)60367-5.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet. 2010;376(9753):1670- 1681. doi:10.1016/S0140-6736(10)61350-5.

Semenkovich CF, Goldberg AC, Goldberg IJ. Disorders of Lipid Metabolism. In: Williams Text-book of Endocrinology. Elsevier; 2011:1633-1674. doi:10.1016/B978-1-4377-0324-5.00037-7.

Miettinen TA. Diurnal variation of cholesterol precursors squalene and methyl sterols in human

Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opinion on Drug Safety. 2015;14(6):935-955. doi:10.1517/14740338.201 5.1039980.

Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. JAC. 2016;67(20):2395-2410. doi:10.1016/j.jacc.2016.02.071.

de Denus S, Spinler SA, Miller K, Peterson AM. Statins and Liver Toxicity: A Meta‐Analysis. Phar-macotherapy: The Journal of Human Pharmacology and Drug Therapy. 2004;24(5):584-591. doi:10.1592/phco.24.6.584.34738. 1

Bays H, Cohen DE, Chalasani N, Liver SHAABTS, 2014. The National Lipid Association’s Statin Safety Task Force.

Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. American Journal of Cardiology. 2002;90(10):1084-1091. doi:10.1016/S0002-9149(02)02774-1.

Bissonnette S, Habib R, Sampalis F, Boukas S, Sampalis JS. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study – the Ezetrol® Add-On Study. Canadian Journal of Cardiology. 2006;22(12):1035-1044. doi:10.1016/S0828-282X(06)70319-1.

Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003;57(5):363-368.

McKenney JM, Farnier M, Lo K-W, et al. Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia. JAC. 2006;47(8):1584-1587. doi:10.1016/j.jacc.2005.11.072.

Sando KR, Knight M. Nonstatin Therapies for Management of Dyslipidemia: A Review. Clinical Therapeutics. 2015;37(10):2153-2179. doi:10.1016/j.clinthera.2015.09.001.

Dorr AE, Gundersen K, Schneider JC, Spencer TW, Martin WB. ColesTipol hydrochloride in hyper-cholesterolemic patients—Effect on serum cholesterol and mortality. Journal of Chronic Diseases. 1978;31(1):5-14. doi:10.1016/0021-9681(78)90076-0.

Zhao X-Q, Krasuski RA, Baer J, et al. Effects of Combination Lipid Therapy on Coronary Stenosis Progression and Clinical Cardiovascular Events in Coronary Disease Patients With Metabolic Syndrome: A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). American Journal of Cardiology. 2009;104(11):1457-1464. doi:10.1016/j.amj-card.2009.07.035.

Rader DJ, Haffner SM. Role of fibrates in the management of hypertriglyceridemia. American Journal of Cardiology. 1999;83(9):30-35. doi:10.1016/S0002-9149(99)00270-2.

Hulley SB, Rosenman RH, Journal RBNE, 1980. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. Mass Medical Soc

Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics. 2010;126(3):314-345. doi:10.1016/j.pharmthera.2010.01.008.

Grundy SM, Arai H, Barter P, et al. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia: Executive summary. Atherosclerosis. 2014;232(2):410-413. doi:10.1016/j. athero-sclerosis.2013.11.031.

Vittone F, Chait A, Morse JS, Fish B, Brown BG, Zhao X-Q. Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: A subgroup analysis of the HDL-Atherosclerosis treatment study. Journal of Clinical Lipidology. 2007;1(3):203-210. doi:10.1016/j.jacl.2007.05.003.

Kris-Etherton PM, Harris WS, Appel LJ, Committee FTN. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Circulation. 2002;106(21):2747-2757. doi:10.1161/01. CIR.0000038493.65177.94.

Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study). American Journal of Cardiology. 2012;110(7): 984-992. doi:10.1016/j.amjcard.2012.05.031.

Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial). American Journal of Cardiology. 2011;108(5):682-690. doi:10.1016/j.amjcard.2011.04.015.

Baum SJ, Cannon CP. PCSK9 inhibitor valuation: A science-based review of the two recent models. Clin Cardiol. 2018;23(3):183. doi:10.1002/clc.22924.

Abifadel M, Varret M, Rabès J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics 2013 45:11. 2003;34(2):154-156. doi:10.1038/ng1161.

Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature Genetics 2013 45:11. 2005;37(2):161- 165. doi:10.1038/ng1509.

Health Quality Ontario. Low-density lipoprotein apheresis: an evidence-based analysis. Ontario Health Technology Assessment Series. 2007;7(5):1-101.

Thompsen J, Atherosclerosis PT, 2006. A Systematic Review of LDL Apheresis in the Treatment of Cardiovascular Disease.

Published

January 5, 2022

License

License